Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 5/20 | 0.54 |
| ▸ | FLT3 | P36888 | 13/20 | 0.52 |
| ▸ | KIT | P10721 | 6/20 | 0.52 |
| ▸ | KDR | P35968 | 4/20 | 0.52 |
| ▸ | FLT1 | P17948 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL64812 | 0.97 | AURKA (0.56) | AURKAFLT3KITKDRFLT1 | |
| SCHEMBL64236 | 0.87 | FLT3 (0.56) | AURKAFLT3KITKDRFLT1 | |
| SCHEMBL63512 | 0.86 | FLT3 (0.49) | AURKAFLT3KITKDRFLT1 | |
| SCHEMBL62764 | 0.85 | MAPT (0.51) | FLT3KITKDRFLT1NPC1 | |
| SCHEMBL63795 | 0.84 | FLT3 (0.47) | AURKAFLT3KITKDRFLT1 | |
| SCHEMBL64062 | 0.84 | FGFR1 (0.55) | FLT3KITKDRFLT1NPC1 | |
| SCHEMBL63357 | 0.83 | KIT (0.55) | AURKAFLT3KITKDRFLT1 | |
| SCHEMBL64243 | 0.82 | AURKA (0.52) | AURKAFLT3KITKDRFLT1 | |
| SCHEMBL62536 | 0.82 | FLT3 (0.62) | AURKAFLT3KITKDRNPC1 | |
| SCHEMBL63445 | 0.81 | F10 (0.55) | KDRNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2125748-A2 | ACYLAMINOPYRAZOLES AS FGFR INHIBITORS | AstraZeneca AB (SE) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008075068-A2 | ACYLAMINOPYRAZOLES AS FGFR INHIBITORS | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | disclosed |